Skip to main content Accessibility help

Understanding and managing cardiac side-effects of second-generation antipsychotics in the treatment of schizophrenia

  • Mark Sweeney (a1), Eromona Whiskey (a2), Rishi K. Patel (a3), Derek K. Tracy (a4), Sukhi S. Shergill (a5) and Carla M. Plymen (a6)...


Second-generation antipsychotic medications (SGAs) have advanced the treatment of schizophrenia over the past 30 years. However, a number of potentially life-threatening cardiac side-effects associated with these treatments concern and can discourage prescribers from administering these evidence-based treatments. This review provides a practical, psychiatrist-oriented understanding of the relative frequencies, mechanisms, investigations and treatments associated with these cardiac toxicities. We aim to highlight that these are relatively rare complications of an effective class of drug and to promote the advantages of early involvement of cardiologists in the psychiatric multidisciplinary team to guide the investigation and management of these conditions.


After reading this article you will be able to:

  • understand the relative incidence of cardiotoxic side-effects of the various SGAs
  • perform preliminary investigations to diagnose the common cardiotoxic side-effects of SGAs
  • understand the treatments for these cardiac side-effects and the role of cardiologists involved the care of these patients.


Corresponding author

Correspondence Mark Sweeney, Department of Cardiology, Hammersmith Hospital, Du Cane Road, London W12 0HS, UK. Email:


Hide All




Hide All
Abdelmawla, N, Mitchell, AJ (2006) Sudden cardiac death and antipsychotics. Part 1: Risk factors and mechanisms. Advances in Psychiatric Treatment, 12: 3544.
Al Ali, AM, Straatman, LP, Allard, MF, et al. (2006) Eosinophilic myocarditis: case series and review of literature. Canadian Journal of Cardiology, 22: 1233–7.
Alawami, M, Wasywich, C, Cicovic, A, et al. (2014) A systematic review of clozapine induced cardiomyopathy. International Journal of Cardiology, 176: 315–20.
Allergan plc. Saphris (Asenapine) [package insert]. US Food and Drug Administration website, 2019 (
Barak, Y, Mirecki, I, Knobler, HY, et al. (2004) Suicidality and second generation antipsychotics in schizophrenia patients: a case-controlled retrospective study during a 5-year period. Psychopharmacology (Berl), 175: 215–9.
Barnes, TR, Leeson, VC, Paton, C, et al. (2017) Amisulpride augmentation in clozapine-unresponsive schizophrenia (AMICUS): a double-blind, placebo-controlled, randomised trial of clinical effectiveness and cost-effectiveness. Health Technology Assessment, 21(49): 156.
Bellissima, BL, Tingle, MD, Cicović, A, et al. (2018) A systematic review of clozapine-induced myocarditis. International Journal of Cardiology, 259: 122–9.
Berk, M, Fitzsimons, J, Lambert, T, et al. (2007) Monitoring the safe use of clozapine. CNS Drugs, 21: 117–27.
Bhatia, MS, Gupta, R, Dhawan, J (2009) Myocarditis after overdose of conventional antipsychotics. World Journal of Biological Psychiatry, 10: 606–8.
Bonnemeier, H, Wiegand, UKH, Braasch, W, et al. (2003) Circadian profile of QT interval and QT interval variability in 172 healthy volunteers. Pacing and Clinical Electrophysiology, 26: 377–82.
Brambatti, M, Matassini, MV, Adler, ED, et al. (2017) Eosinophilic myocarditis. Journal of the American College of Cardiology, 70: 2363–75.
Caforio, AL, Pankuweit, S, Arbustini, E, et al. (2013) Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. European Heart Journal, 34: 2636–48.
Cirincione, B, Sager, PT, Mager, DE (2017) Influence of meals and glycemic changes on QT interval dynamics. Journal of Clinical Pharmacology, 57: 966–76.
Conley, RR (1998) Optimizing treatment with clozapine. Journal of Clinical Psychiatry, 59(suppl 3): 44–8.
Cowie, MR, Struthers, AD, Wood, DA, et al. (1997) Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet, 350: 1349–53.
Das, P, Kuppuswamy, PS, Rai, A, et al. (2014) Verapamil for the treatment of clozapine-induced persistent sinus tachycardia in a patient with schizophrenia: a case report and literature review. Psychosomatics, 55: 194–5.
de Leon, J, Tang, Y-L, Baptista, T, et al. (2015) Titrating clozapine amidst recommendations proposing high myocarditis risk and rapid titrations. Acta Psychiatrica Scandinavica, 132: 242–3.
Degner, D, Bleich, S, Grohmann, R, et al. (2000) Myocarditis associated with clozapine treatment. Australian & New Zealand Journal of Psychiatry, 34: 880.
Fanoe, S, Kristensen, D, Fink-Jensen, A, et al. (2014) Risk of arrhythmia induced by psychotropic medications: a proposal for clinical management. European Heart Journal, 35: 1306–15.
Floreani, J, Bastiampillai, T (2008) Successful re-challenge with clozapine following development of clozapine-induced cardiomyopathy. Australian and New Zealand Journal of Psychiatry, 42: 747–8.
Grün, S, Schumm, J, Greulich, S, et al. (2012) Long-term follow-up of biopsy-proven viral myocarditis: predictors of mortality and incomplete recovery. Journal of the American College of Cardiology, 59: 1604–15.
Haas, SJ, Hill, R, Krum, H, et al. (2007) Clozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993–2003. Drug Safety, 30: 4757.
Hassan, I, Brennan, A, Carroll, A, et al. (2011) Monitoring in clozapine rechallenge after myocarditis. Australasian Psychiatry, 19: 370–1.
Ifteni, P, Correll, CU, Burtea, V, et al. (2014) Sudden unexpected death in schizophrenia: autopsy findings in psychiatric inpatients. Schizophrenia Research, 155: 72–6.
Janssen Pharmaceutica NV Haldol (Haloperidol) [package insert]. US Food and Drug Administration website, 2019 (,018701s057lbl.pdf).
Khan, AA, Ashraf, A, Baker, D, et al. (2017) Clozapine and incidence of myocarditis and sudden death: long term Australian experience. International Journal of Cardiology, 238: 136–9.
Kilian, JG, Kerr, K, Lawrence, C, et al. (1999) Myocarditis and cardiomyopathy associated with clozapine. Lancet, 354: 1841–5.
Kiviniemi, M, Suvisaari, J, Koivumaa-Honkanen, H, et al. (2013) Antipsychotics and mortality in first-onset schizophrenia: prospective Finnish register study with 5-year follow-up. Schizophrenia Research, 150: 274–80.
Knoph, KN, Morgan, RJ, Palmer, BA, et al. (2018) Clozapine-induced cardiomyopathy and myocarditis monitoring: a systematic review. Schizophrenia Research, 199: 1730.
Kongsamut, S, Kang, J, Chen, X-L, et al. (2002) A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs. European Journal of Pharmacology, 450: 3741.
La Grenade, L, Graham, D, Trontell, A (2001) Myocarditis and cardiomyopathy associated with clozapine use in the United States. New England Journal of Medicine, 345: 224–5.
Lally, J, Brook, J, Dixon, T, et al. (2014) Ivabradine, a novel treatment for clozapine-induced sinus tachycardia: a case series. Therapeutic Advances in Psychopharmacology, 4: 117–22.
Lally, J, Docherty, MJ, MacCabe, JH (2016) Pharmacological interventions for clozapine-induced sinus tachycardia. Cochrane Database of Systematic Reviews, 6: CD011566 (doi: 10.1002/14651858.CD011566.pub2).
Lauer, B, Niederau, C, Kühl, U, et al. (1997) Cardiac troponin T in patients with clinically suspected myocarditis. Journal of the American College of Cardiology, 30: 1354–59.
Leucht, S, Corves, C, Arbter, D, et al. (2009) Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet, 373: 3141.
Leucht, S, Cipriani, A, Spineli, L, et al. (2013) Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet, 382: 951–62.
Loebel, A, Cucchiaro, J, Sarma, K, et al. (2013) Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial. Schizophrenia Research, 145: 101–9.
Magnano, AR, Holleran, S, Ramakrishnan, R, et al. (2002) Autonomic nervous system influences on QT interval in normal subjects. Journal of the American College of Cardiology, 39: 1820–6.
Marinkovic, D, Timotijevic, I, Babinski, T, et al. (1994) The side-effects of clozapine: a four year follow-up study. Progress in Neuropsychopharmacology and Biolical Psychiatry, 18: 537–44.
Merrill, DB, Dec, GW, Goff, DC (2005) Adverse cardiac effects associated with clozapine. Journal of Clinical Psychopharmacology, 25: 3241.
Meyer-Massetti, C, Cheng, CM, Sharpe, BA, et al. (2010) The FDA extended warning for intravenous haloperidol and torsades de pointes: how should institutions respond? Journal of Hospital Medicine, 5: E816.
Montastruc, G, Favreliere, S, Sommet, A, et al. (2010) Drugs and dilated cardiomyopathies: a case/noncase study in the French PharmacoVigilance Database. British Journal of Clinical Pharmacology, 69: 287–94.
Murch, S, Tran, N, Liew, D, et al. (2013) Echocardiographic monitoring for clozapine cardiac toxicity: lessons from real-world experience. Australasian Psychiatry, 21: 258–61.
Nakonezny, PA, Byerly, MJ (2006) Electronically monitored adherence in outpatients with schizophrenia or schizoaffective disorder: a comparison of first- vs. second-generation antipsychotics. Schizophrenia Research, 82: 107–14.
National Institute for Health and Care Excellence (2018) Chronic Heart Failure in Adults: Diagnosis and Management (NICE Guideline NG106). NICE.
Nederlof, M, Benschop, TW, de Vries Feyens, CA, et al. (2017) clozapine re-exposure after dilated cardiomyopathy. BMJ Case Reports, 2017: bcr-2017-219652.
Nilsson, BM, Edström, O, Lindström, L, et al. (2017) Tachycardia in patients treated with clozapine versus antipsychotic long-acting injections. International Clinical Psychopharmacology, 32: 219–24.
Patel, PJ, Borovskiy, Y, Killian, A, et al. (2016) Optimal QT interval correction formula in sinus tachycardia for identifying cardiovascular and mortality risk: findings from the Penn Atrial Fibrillation Free Study. Heart Rhythm, 13: 527–35.
Patriki, D, Gresser, E, Manka, R, et al. (2018) Approximation of the incidence of myocarditis by systematic screening with cardiac magnetic resonance imaging. JACC: Heart Failure, 6: 573–9.
Perälä, J, Suvisaari, J, Saarni, SI, et al. (2007) Lifetime prevalence of psychotic and bipolar I disorders in a general population. Archives of General Psychiatry, 64: 19–28.
Polcwiartek, C, Sneider, B, Graff, C, et al. (2015) The cardiac safety of aripiprazole treatment in patients at high risk for torsade: a systematic review with a meta-analytic approach. Psychopharmacology, 232: 3297–308.
Polcwiartek, C, Kragholm, K, Schjerning, O, et al. (2016) Cardiovascular safety of antipsychotics: a clinical overview. Expert Opinion on Drug Safety, 15: 679–88.
Ponikowski, P, Voors, AA, Anker, SD, et al. (2016) 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal, 37: 2129–200.
Priori, SG, Blomström-Lundqvist, C, Mazzanti, A, et al. (2015) 2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. European Heart Journal, 36: 2793–867.
Quigley, PJ, Richardson, PJ, Meany, BT, et al. (1987) Long-term follow-up of acute myocarditis. Correlation of ventricular function and outcome. European Heart Journal, 8(suppl): 3942.
Rakar, S, Sinagra, G, Di Lenarda, A, et al. (1997) Epidemiology of dilated cardiomyopathy. a prospective post-mortem study of 5252 necropsies. European Heart Journal, 18: 117–23.
Rautaharju, PM, Surawicz, B, Gettes, LS, et al. (2009) AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram. Journal of the American College of Cardiology, 53: 982–91.
Ray, WA, Chung, CP, Murray, KT, et al. (2009) Atypical antipsychotic drugs and the risk of sudden cardiac death. New England Journal of Medicine, 360: 225–35.
Reinders, J, Parsonage, W, Lange, D, et al. (2004) Clozapine-related myocarditis and cardiomyopathy in an Australian metropolitan psychiatric service. Australian & New Zealand Journal of Psychiatry, 38: 915–22.
Roden, DM (2004) Drug-induced prolongation of the QT interval. New England Journal of Medicine, 350: 1013–22.
Roesch-Ely, D, Van Einsiedel, R, Kathöfer, S, et al. (2002) Myocarditis with quetiapine. American Journal of Psychiatry, 159: 1607–8.
Rohde, C, Polcwiartek, C, Kragholm, K, et al. (2018) Adverse cardiac events in out-patients initiating clozapine treatment: a nationwide register-based study. Acta Psychiatrica Scandinavica, 137: 4753.
Ronaldson, KJ, Taylor, AJ, Fitzgerald, PB, et al. (2010) Diagnostic characteristics of clozapine-induced myocarditis identified by an analysis of 38 cases and 47 controls. Journal of Clinical Psychiatry, 71: 976–81.
Ronaldson, KJ, Fitzgerald, PB, Taylor, AJ, et al. (2011a) Clinical course and analysis of ten fatal cases of clozapine-induced myocarditis and comparison with 66 surviving cases. Schizophrenia Research, 128: 161–5.
Ronaldson, KJ, Fitzgerald, PB, Taylor, AJ, et al. (2011b) A new monitoring protocol for clozapine-induced myocarditis based on an analysis of 75 cases and 94 controls. Australian & New Zealand Journal of Psychiatry, 45: 458–65.
Ronaldson, KJ, Fitzgerald, PB, Taylor, AJ, et al. (2012a) Observations from 8 cases of clozapine rechallenge after development of myocarditis. Journal of Clinical Psychiatry, 73: 252–4.
Ronaldson, KJ, Fitzgerald, PB, Taylor, AJ, et al. (2012b) Rapid clozapine dose titration and concomitant sodium valproate increase the risk of myocarditis with clozapine: a case–control study. Schizophrenia Research, 141: 173–8.
Ronaldson, KJ, Fitzgerald, PB, Taylor, AJ, et al. (2012c) Continuation of clozapine following mild myocarditis. Australian & New Zealand Journal of Psychiatry, 46: 910–11.
Ronaldson, KJ, Fitzgerald, PB, McNeil, JJ (2015a) Evolution of troponin, C-reactive protein and eosinophil count with the onset of clozapine-induced myocarditis. Australian & New Zealand Journal of Psychiatry, 49: 486–7.
Ronaldson, KJ, Fitzgerald, PB, McNeil, JJ (2015b) Clozapine-induced myocarditis, a widely overlooked adverse reaction. Acta Psychiatrica Scandinavica, 132: 231–40.
Sahpaz, A, Pehlivan, S, Turkkan, D, et al. (2016) Eosinophilic myocarditis in long term use of antipsychotics: case series and review of the literature. Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology, 26(4): 417–21.
Sanchez, AYA, Foster, JJ, Plymen, CM, et al. (2016) Clozapine in a patient with treatment-resistant schizophrenia and hypertrophic cardiomyopathy: a case report. BJPsych Open, 2: 390–3.
Scelsa, SN, Simpson, DM, McQuistion, HL, et al. (1996) Clozapine-induced myotoxicity in patients with chronic psychotic disorders. Neurology, 47: 1518–23.
Sernyak, MJ, Desai, R, Stolar, M, et al. (2001) Impact of clozapine on completed suicide. American Journal of Psychiatry, 158: 931–7.
Suter, TM, Procter, M, van Veldhuisen, DJ, et al. (2007) Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. Journal of Clinical Oncology, 25: 3859–65.
Tirupati, S (2006) Clozapine and heart in the Hunter region. Australian and New Zealand Journal of Psychiatry, 40: 97.
Vandenberk, B, Vandael, E, Robyns, T, et al. (2016) Which QT correction formulae to use for QT monitoring? Journal of the American Heart Association, 5(6): e003264.
Vang, T, Rosenzweig, M, Bruhn, CH, et al. (2016) Eosinophilic myocarditis during treatment with olanzapine: report of two possible cases. BMC Psychiatry, 16: 70.
Warner, B, Alphs, L, Schaedelin, J, et al. (2000) Clozapine and sudden death. Lancet, 355: 842.
Wassef, N, Khan, N, Munir, S (2015) Quetiapine-induced myocarditis presenting as acute STEMI. BMJ Case Reports, 2015: bcr2014207151.
Wu, C-S, Tsai, Y-T, Tsai, H-J (2015) Antipsychotic drugs and the risk of ventricular arrhythmia and/or sudden cardiac death: a nation-wide case-crossover study. Journal of the American Heart Association, 4(2) e001568.
Yap, YG, Camm, AJ (2003) Drug induced QT prolongation and torsades de pointes. Heart, 89: 1363–72.
Zamorano, JL, Lancellotti, P, Rodriguez Muñoz, D, et al. (2016) 2016 ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. European Heart Journal, 37: 2768–801.


Related content

Powered by UNSILO

Understanding and managing cardiac side-effects of second-generation antipsychotics in the treatment of schizophrenia

  • Mark Sweeney (a1), Eromona Whiskey (a2), Rishi K. Patel (a3), Derek K. Tracy (a4), Sukhi S. Shergill (a5) and Carla M. Plymen (a6)...


Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed.

Understanding and managing cardiac side-effects of second-generation antipsychotics in the treatment of schizophrenia

  • Mark Sweeney (a1), Eromona Whiskey (a2), Rishi K. Patel (a3), Derek K. Tracy (a4), Sukhi S. Shergill (a5) and Carla M. Plymen (a6)...
Submit a response


No eLetters have been published for this article.


Reply to: Submit a response

Your details

Conflicting interests

Do you have any conflicting interests? *